A Prospective Study on the Efficacy and Safety of CD8+NKG2D+ AKT cell immunotherapy to the pancreatic cancer patients treated with adjuvant chemotherapy.

Inclusion Criteria:

• 1. Diagnosed as stage II-III pancreatic ductal adenocarcinoma patients by pathologic histology;
• 2. Pancreatic cancer after radical resection;
• 3. Eastern Cooperative Oncology Group Performance Status less than 2;
• 4. Without radiotherapy or neoadjuvant chemotherapy;
• 5. The man or the gestation and lactation women Age between 18 to 80 years old;
• 6. Bone marrow functioned well: ANC more than 1.5*10^9/ L, PLT more than 100*10^9/LHgb more than 9 g/dL;
• 7. Blood biochemical indicators: AST（SGOT）less than 1.5 ULNALT（SGPT）less than 1.5 ULN, TBIL less than 1.5 ULN;
• 8. PT and PPT are in normal ranges;
• 9. Three months prior to clinical research did not receive any other clinical research trials;
• 10. patients are voluntary, and willing to sign informed consent.

Exclusion Criteria:

• 1. Patients with other malignant tumors in the past five years;
• 2. Active viral or bacterial infection and cannot be controlled with appropriate anti-infection treatment;
• 3. Known as HIV infection, active hepatitis B virus or hepatitis C virus infection;
• 4. Known allergy to any kind of component of study drugs;
• 5. History of connective tissue disease(Such as lupus, scleroderma, nodular arteritis);
• 6. Patients with a history of interstitial pneumoniaSlowly progressive difficulty in breathing and hoose Sarcoidosissilicosis Fibrose pulmonaire idiopathiquehylactic pneumonia or A variety of allergy;
• 7. Suffering from mental illness or other illness, such as heart or lung disease, diabetes, etc. that can not be controlled, and can not cope with study treatment and monitoring requirements;
• 8. At the same time Patients participate in any other use of interventional medicine clinical research or checkers.